Trials / Recruiting
RecruitingNCT07247110
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-4716 | Oral administration |
| BIOLOGICAL | Pembrolizumab | Intravenous administration |
| BIOLOGICAL | Cetuximab | Intravenous administration |
Timeline
- Start date
- 2025-12-16
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2025-11-25
- Last updated
- 2026-04-13
Locations
15 sites across 6 countries: United States, Australia, Chile, Israel, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07247110. Inclusion in this directory is not an endorsement.